Suchen
Urogen Pharma Ltd
URGNZur Watchlist hinzufügen
37.940USD
+1.140+3.10%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
1.85BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Urogen Pharma Ltd Unternehmen
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd Informationen
BörsenkürzelURGN
Name des UnternehmensUrogen Pharma Ltd
IPO-datumMay 04, 2017
CEOBarrett (Elizabeth A)
Anzahl der mitarbeiter235
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse9 Ha'ta'asiya St
StadtRA'ANANA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl4365007
Telefon97297707601
Websitehttps://www.urogen.com/
BörsenkürzelURGN
IPO-datumMay 04, 2017
CEOBarrett (Elizabeth A)
Führungskräfte von Urogen Pharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Urogen Pharma Ltd?
Die fünf größten Anteilseigner von Urogen Pharma Ltd sind: Dr. Arie S. Belldegrun, M.D.
Wie viele Institutionen halten Anteile an Urogen Pharma Ltd (URGN)?
Mit Stand vom 2026Q1 halten 349 Institutionen Anteile an Urogen Pharma Ltd, mit einem Gesamtmarktwert von etwa 46.29M, was 95.00% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -15691017.00 gestiegen.
Was ist die größte Einnahmequelle von Urogen Pharma Ltd?
Am 2026Q1 erzielte das Geschäft mit Jelmyto für Urogen Pharma Ltd den höchsten Umsatz in Höhe von 93.99M, was 85.61% des Gesamtumsatzes entspricht.